Edgewood Oncology
A clinical-stage biotech company developing treatments for hematologic malignancies and genetically-defined solid tumors.
The company's lead candidate, BTX-A51, is a novel small molecule, multi-kinase inhibitor that synergistically co-targets master regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically-defined solid tumors, which are the focus of ongoing clinical programs.
Latest Edgewood Oncology News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze